The project, which aims to develop drugs that will cure brain cancer, and which is led by Assoc. Prof. Nurettin Mengeş, Lecturer at the Department of Biomedical Engineering, Faculty of Engineering, Necmettin Erbakan University (NEU), was found worthy of support by the Presidency of Turkish Health Institutes (TÜSEB), which supports drug and vaccine research within the Ministry of Health.
The project titled "Synthesis of New Species Imidazopiridine and Its Analogues, Antiproliferative Effect on Glioblastoma, Determination of Mechanism of Action and Conducting Pharmacokinetic Tests for Candidate Molecules" to be carried out within the body of NEU Central Laboratory Science and Technology Research Center (BITAM) was presented in the field of strategic drug research and development. The study aims to develop new drug candidates related to glioblastoma, the most aggressive form of brain cancer, and move them into the phase stages.
Assoc. Prof. Dr. Nurettin Mengeş, Lecturer at NEU Department of Biomedical Engineering, who gave information on the subject, said, "If a candidate molecule to be developed through the project is moved to the phase stage, we foresee that it will create an important potential for our country in drug research. Within the scope of the project, we will make an intensive effort for a new drug treatment of glioblastoma, which is a type of cancer with a very high mortality rate and unfortunately the definitive treatment has not yet been found."